DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis
In: Biochimica et Biophysica Acta (BBA) - General Subjects, Jg. 1861 (2017-11-01), S. 2690-2701
Online
unknown
Zugriff:
Background The nuclear receptor PPARγ is an effective pharmacological target for some types of metabolic syndrome, including obesity, diabetes, nonalcoholic fatty liver disease, and cardiovascular disease. However, the current PPARγ-targeting thiazolidinedione drugs have undesirable side effects. Danshensu Bingpian Zhi (DBZ), also known as tanshinol borneol ester derived from Salvia miltiorrhiza , is a synthetic derivative of natural compounds used in traditional Chinese medicine for its anti-inflammatory activity. Methods In vitro , investigations of DBZ using a luciferase reporter assay and molecular docking identified this compound as a novel promising PPARγ agonist. Ten-week-old C57BL/6J mice were fed either a normal chow diet (NCD) or a high-fat diet (HFD). The HFD-fed mice were gavaged daily with either vehicle or DBZ (50 mg/kg or 100 mg/kg) for 10 weeks. The gut microbiota composition was assessed by analyzing the 16S rRNA gene V3 + V4 regions via pyrosequencing. Results DBZ is an efficient natural PPARγ agonist that shows lower PPARγ-responsive luciferase reporter activity than thiazolidinediones, has excellent effects on the metabolic phenotype and exhibits no unwanted adverse effects in a HFD-induced obese mouse model. DBZ protects against HFD-induced body weight gain, insulin resistance, hepatic steatosis and inflammation in mice. DBZ not only stimulates brown adipose tissue (BAT) browning and maintains intestinal barrier integrity but also reverses HFD-induced intestinal microbiota dysbiosis. Conclusions DBZ is a putative PPARγ agonist that prevents HFD-induced obesity-related metabolic syndrome and reverse gut dysbiosis. General significance DBZ may be used as a beneficial probiotic agent to improve HFD-induced obesity-related metabolic syndrome in obese individuals.
Titel: |
DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis
|
---|---|
Autor/in / Beteiligte Person: | Xu, Pengfei ; Zheng, Xiaohui ; Hong, Fan ; Wang, Sheng ; Wang, Jing ; Xue, Tingting ; Xu, Jingwei ; Wang, Jialin ; Zhai, Yonggong ; Zhao, Xia |
Link: | |
Zeitschrift: | Biochimica et Biophysica Acta (BBA) - General Subjects, Jg. 1861 (2017-11-01), S. 2690-2701 |
Veröffentlichung: | Elsevier BV, 2017 |
Medientyp: | unknown |
ISSN: | 0304-4165 (print) |
DOI: | 10.1016/j.bbagen.2017.07.013 |
Schlagwort: |
|
Sonstiges: |
|